A multidisciplinary area involving Molecular Biology, Fermentation, Microbiology, Protein Purification, Analytical Methods and Genetic Engineering knowledge. It develops genetically modified organisms - bacteria, specifically - which receive human genes and become the active ingredient of new medication. Eurofarma has invested around R$ 40 million in the biotechnological platform.
In 2005, Eurofarma has built its Biotechnology Laboratory at the Interlagos Unit, in São Paulo, beginning the activities in the following year. In 2007, the company produced four pilot batches of the first biotech drug, the Filgrastim, for the treatment of cancer patients. At this stage, all scientific steps have been performed, from the development of the clone to the analytical methodology. Its production is quite complex, as it involves the modification of the DNA of a living organism, requiring distinctly different processes from a synthetic product.
Fiprima® (filgrastim) hit the market in 2016, indicated to induce an increase in the body’s defense cells in patients with some types of cancer, such as breast and leukemia, preventing the emergence of opportunistic infectious diseases. The aging population is generating an increase in the incidence of diseases such as cancer and Alzheimer’s, and the use of biological drugs to fight these diseases is a worldwide trend.
In addition to serving the private market, Eurofarma has an ongoing agreement with the Bio-Manguinhos/Fiocruz Institute, via a partnership for the Productive Development (PDP), to provide the medicine to the public market, through the technology transfer.